Page 3 - Sheet Information News Today

Press release content from Business Wire. The AP news staff was not involved in its creation.

The following discussion provides information that management believes is relevant to an understanding and assessment of the consolidated financial condition and results of operations of Ventas, Inc.... | February 18, 2022

/PRNewswire/ -- PBF Logistics LP (NYSE:PBFX, the "Partnership") announced today fourth quarter 2021 net income attributable to the limited partners of $42.3...

/PRNewswire/ -- PBF Logistics LP (NYSE:PBFX, the "Partnership") announced today fourth quarter 2021 net income attributable to the limited partners of $42.3...

/PRNewswire/ -- PBF Logistics LP (NYSE:PBFX, the "Partnership") today announced third quarter 2021 net income attributable to the limited partners of $36.7...

Press release content from Business Wire. The AP news staff was not involved in its creation.

NON-GAAP MEASURES To supplement our financial information presented in this offering memorandum that are presented in accordance with generally accepted... | October 12, 2021

Second quarter revenues were $1.4 billion – flat compared with the prior year period for Wyndham Hotel Group. In constant currency and excluding acquisitions, revenues increased 1%. Net income for the second quarter of 2016 was $156 million, or $1.39 per diluted share, compared with $159 million, or $1.33 per diluted share, for the second quarter of 2015. Adjusted net income for the second quarter of 2016 was $156 million, or $1.40 per diluted share, compared with $159 million, or $1.32 per ...

Published: May 10, 2021 NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2021. “We continued to make significant strides in the quarter toward becoming a premier biopharmaceutical company focused on delivering potentially life-changing medicines to people living with ...

AXS-07 for migraine, NDA submission (2Q 2021) AXS-05 for smoking cessation, FDA meeting (3Q 2021) AXS-05 for MDD, commercial launch, if approved (2H 2021) Clinical Trial Readouts: Clinical Trial Initiations: Upcoming Scientific Conferences International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting, May 17-20, 2021 American Society for Clinical Psychopharmacology (ASCP) annual meeting, June 1-4, 2021 American Headache Society (AHS) annual meeting, June 3-6, 2021 Upc...